Search results
Author(s):
Raban Jeger
,
Thomas Nestelberger
Added:
3 years ago
Coronary artery disease (CAD) remains a major cause of morbidity and mortality despite major improvements in primary and secondary prevention strategies. Percutaneous coronary intervention (PCI) or surgical revascularisation may be indicated in many patients with acute or stable CAD.1
Since the first coronary intervention using catheter mounted balloons, percutaneous treatment of CAD has evolved…
View more
Author(s):
Ehrin J Armstrong
,
Stephen W Waldo
Added:
3 years ago
Patients with diabetes mellitus (DM) have an increased prevalence of coronary artery disease (CAD) and are more likely to require coronary revascularisation than patients without DM.1 Similar to the general population, CAD remains the most frequent cause of death among patients with DM.2 As the prevalence of DM continues to rise worldwide, the appropriate management and method of…
View more
Author(s):
Pantelis Diamantouros
,
David Kandzari
Added:
3 years ago
In both randomised trials, compared with bare metal coronary stents, and in observational registries, treatment with drug-eluting stents (DES) has been associated with considerable reductions in angiographic restenosis and the need for repeat coronary revascularisation procedures. Despite these established benefits in selected patient populations, relatively little is known regarding the safety…
View more
Author(s):
Greg Murphy
,
Ailish Naughton
,
Rory Durand
,
et al
Added:
11 months ago
Author(s):
Robert A Byrne
,
Eric Eeckhout
,
Gennaro Sardella
,
et al
Added:
3 years ago
Percutaneous coronary intervention (PCI) and coronary artery bypass grafting (CABG) are established strategies for revascularisation in patients with coronary artery disease. While CABG was the standard of care for patients with multivessel disease, the introduction of baremetal stents (BMSs) and, later, drug-eluting stents (DESs) has led to an increased use of PCI in these more challenging cases…
View more
Author(s):
Mehdi Shishehbor
Added:
1 year ago
In this late-breaking interview from ACC.22, Dr Mehdi Shishehbor (University Hospitals Cleveland Medical Center, Cleveland, OH, US) discusses the outcomes of the Chocolate-Touch study, a multicentre prospective trial investigating the safety and effectiveness of the Chocolate Touch™ paclitaxel-coated balloon in superficial femoral or popliteal arteries compared to the commercially available…
View more
Advances in New Stent Designs without a Permanent Polymer May Solve Polymer-related Complications
Author(s):
Chourmouzios A Arampatzi
,
Raul Moreno
,
Giuseppe Sangiorgi
Added:
3 years ago
Article
Author(s):
Gaku Nakazawa
,
Masataka Nakano
,
Marc Vorpahl
,
et al
Added:
3 years ago
The limited information regarding the long-term safety of drug-eluting stents (DES) for the treatment of ST-segment-elevation myocardial infarction (STEMI) has raised concern regarding its clinical safety, in particular with respect to the associated morbidity and mortality attributed to late stent thrombosis (LST). Observational studies in daily practice have shown that the risk of LST continues…
View more
Author(s):
Rafael Romaguera
Added:
2 years ago
In this short interview, Dr Rafael Romaguera (University of Barcelona, SP) discusses the findings from the SUGAR trial.This randomized head-to-head trial aimed to compare Cre8 EVO stents to a contemporary drug-eluting stent (DES) in patients with diabetes (DM) and coronary artery disease. The trial, first presented at TCT 2021, demonstrated that Cre8 EVO stents were non-inferior to Resolute Onyx…
View more
Author(s):
Anuj Gupta
,
Issam Moussa
Added:
3 years ago
The treatment of atherosclerotic coronary artery disease (CAD) using percutaneous coronary intervention (PCI) is a well-established procedure that is performed over one million times a year in the US. The Achilles heel of PCI has been the development of neointimal hyperplasia within the stent, resulting in in-stent restenosis (ISR). Sirolimus-eluting stents (SES) provide a platform that in…
View more